Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 7 (2010), Issue 3 (March)

1. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial.
   Lancet, 375(9716): 743-51. [Abstract] [Full-text]
2. Enteral fluid therapy in 108 horses with large colon impactions and dorsal displacements.
   Vet Rec, 166(9): 259-63. [Abstract] [Full-text]
3. Effects of neoadjuvant chemotherapy on hepatoblastoma: a morphologic and immunohistochemical study.
   Am J Surg Pathol, 34(3): 287-99. [Abstract] [Full-text]
4. Hormone replacement therapy in relation to risk of cataract extraction: a prospective study of women.
   Ophthalmology, 117(3): 424-30. [Abstract] [Full-text]
5. Impact of coagulation-balance gene predictors on efficacy of photodynamic therapy for choroidal neovascularization in pathologic myopia.
   Ophthalmology, 117(3): 517-23. [Abstract] [Full-text]
6. Cerebral metabolic alterations in rats with diabetic ketoacidosis: effects of treatment with insulin and intravenous fluids and effects of bumetanide.
   Diabetes, 59(3): 702-9. [Abstract] [Full-text]
7. Phase I/II study of s-1 plus cisplatin combination chemotherapy in patients with advanced/recurrent head and neck cancer.
   Jpn J Clin Oncol, 40(3): 214-21. [Abstract] [Full-text]
8. Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy.
   Fertil Steril, 93(4): 1267-72. [Abstract] [Full-text]
9. The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz-based HAART over 48 weeks: the NOCTE study.
   J Acquir Immune Defic Syndr, 53(3): 369-77. [Abstract] [Full-text]
10. A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy.
    Cancer Chemother Pharmacol, 65(5): 979-88. [Abstract] [Full-text]
11. Provider-focused intervention increases adherence-related dialogue but does not improve antiretroviral therapy adherence in persons with HIV.
    J Acquir Immune Defic Syndr, 53(3): 338-47. [Abstract] [Full-text]
12. An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents.
    Gastroenterology, 138(3): 993-1002.e1. [Abstract] [Full-text]
13. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model.
    Gastroenterology, 138(3): 843-53.e1-2. [Abstract] [Full-text]
14. Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach.
    J Acquir Immune Defic Syndr, 53(3): 405-11. [Abstract] [Full-text]
15. Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy.
    Cancer Chemother Pharmacol, 65(5): 969-78. [Abstract] [Full-text]
16. Slow release antibiotics for treatment of septic arthritis in large animals.
    Vet J, 184(1): 14-20. [Abstract] [Full-text]
17. The management and outcome of women with post-hydatidiform mole 'low-risk' gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l(-1).
    Br J Cancer, 102(5): 810-4. [Abstract] [Full-text]
18. Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth.
    Proc Natl Acad Sci U S A, 107(9): 3966-71. [Abstract] [Full-text]
19. Genetic approach for intracerebroventricular delivery.
    Proc Natl Acad Sci U S A, 107(9): 4424-9. [Abstract] [Full-text]
20. Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma.
    Cancer Immunol Immunother, 59(5): 769-77. [Abstract] [Full-text]
21. Single-session endovascular treatment for symptomatic lower extremity deep vein thrombosis: a feasibility study.
    Acta Radiol, 51(3): 248-55. [Abstract] [Full-text]
22. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience.
    Blood, 115(9): 1690-6. [Abstract] [Full-text]
23. Comparison of favorable early-stage hodgkin's lymphoma treatments: a single-institution review.
    Int J Radiat Oncol Biol Phys, 76(4): 1166-70. [Abstract] [Full-text]
24. Phase II study of vinorelbine and estramustine in combination with conformational radiotherapy for patients with high-risk prostate cancer.
    Int J Radiat Oncol Biol Phys, 76(4): 1085-91. [Abstract] [Full-text]
25. Primary tumor necrosis predicts distant control in locally advanced soft-tissue sarcomas after preoperative concurrent chemoradiotherapy.
    Int J Radiat Oncol Biol Phys, 76(4): 1147-53. [Abstract] [Full-text]
26. Iron/ethylcellulose (core/shell) nanoplatform loaded with 5-fluorouracil for cancer targeting.
    Colloids Surf B Biointerfaces, 77(1): 111-6. [Abstract] [Full-text]
27. Rapid expansion of intravitreal drug injection procedures, 2000 to 2008: a population-based analysis.
    Arch Ophthalmol, 128(3): 359-62. [Abstract] [Full-text]
28. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema.
    Arch Ophthalmol, 128(3): 289-96. [Abstract] [Full-text]
29. Evaluation of contraindications and efficacy of oral Beta blockade before computed tomographic coronary angiography.
    Am J Cardiol, 105(6): 767-72. [Abstract] [Full-text]
30. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.
    J Clin Oncol, 28(8): 1351-7. [Abstract] [Full-text]
31. Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients.
    J Clin Oncol, 28(8): 1329-36. [Abstract] [Full-text]
32. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.
    J Clin Oncol, 28(8): 1387-94. [Abstract] [Full-text]
33. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.
    J Clin Oncol, 28(8): 1422-8. [Abstract] [Full-text]
34. Selective death of human breast cancer cells by lytic immunoliposomes: Correlation with their HER2 expression level.
    Cancer Lett, 290(2): 192-203. [Abstract] [Full-text]
35. Photodynamic therapy-driven induction of suicide cytosine deaminase gene.
    Cancer Lett, 290(2): 216-22. [Abstract] [Full-text]
36. Double high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation for primary disseminated medulloblastoma: a report of 3 cases.
    J Pediatr Hematol Oncol, 32(2): e70-4. [Abstract] [Full-text]
37. Low-dose systemic thrombolytic therapy for deep vein thrombosis in pediatric patients.
    J Pediatr Hematol Oncol, 32(2): 97-102. [Abstract] [Full-text]
38. Photochemotherapy induces the apoptosis of monocytes without impairing their function.
    Transplantation, 89(5): 492-9. [Abstract] [Full-text]
39. Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures.
    J Acquir Immune Defic Syndr, 53(4): 464-71. [Abstract] [Full-text]
40. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa.
    J Acquir Immune Defic Syndr, 53(4): 500-6. [Abstract] [Full-text]
41. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa.
    J Acquir Immune Defic Syndr, 53(4): 480-4. [Abstract] [Full-text]
42. Association between weight gain and clinical outcomes among malnourished adults initiating antiretroviral therapy in Lusaka, Zambia.
    J Acquir Immune Defic Syndr, 53(4): 507-13. [Abstract] [Full-text]
43. Catheter-based therapies for massive pulmonary embolism.
    Prog Cardiovasc Dis, 52(5): 429-37. [Abstract] [Full-text]
44. The impact of different concentrations of sodium tetradecyl sulphate and initial balloon denudation on endothelial cell loss and tunica media injury in a model of foam sclerotherapy.
    Eur J Vasc Endovasc Surg, 39(3): 366-71. [Abstract] [Full-text]
45. Reduction of CD44(+)/CD24(-) breast cancer cells by conventional cytotoxic chemotherapy.
    Hum Pathol, 41(4): 574-81. [Abstract] [Full-text]
46. Total parenteral nutrition in children and adolescents treated with high-dose chemotherapy followed by autologous haematopoietic transplants.
    Br J Nutr, 103(6): 899-906. [Abstract] [Full-text]
47. Abilities of pulse pressure variations and stroke volume variations to predict fluid responsiveness in prone position during scoliosis surgery.
    Br J Anaesth, 104(4): 407-13. [Abstract] [Full-text]
48. An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome.
    Cancer Treat Rev, 36(2): 164-76. [Abstract] [Full-text]
49. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
    Pediatr Blood Cancer, 54(5): 687-93. [Abstract] [Full-text]
50. Biodistribution of a radiolabelled thermoresponsive polymer in mice.
    Appl Radiat Isot, 68(6): 1073-8. [Abstract] [Full-text]
51. Penetration pathways induced by low-frequency sonophoresis with physical and chemical enhancers: iron oxide nanoparticles versus lanthanum nitrates.
    J Invest Dermatol, 130(4): 1063-72. [Abstract] [Full-text]
52. Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer.
    Cancer Chemother Pharmacol, 65(6): 1197-202. [Abstract] [Full-text]
53. A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer.
    Cancer Chemother Pharmacol, 65(6): 1009-21. [Abstract] [Full-text]
54. Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer.
    Cancer Chemother Pharmacol, 65(6): 1101-7. [Abstract] [Full-text]
55. Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients.
    Cancer Chemother Pharmacol, 65(6): 1057-66. [Abstract] [Full-text]
56. Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer.
    JAMA, 303(11): 1037-45. [Abstract] [Full-text]
57. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.
    Br J Cancer, 102(6): 987-94. [Abstract] [Full-text]
58. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.
    Br J Cancer, 102(6): 1003-9. [Abstract] [Full-text]
59. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.
    Br J Cancer, 102(6): 995-1002. [Abstract] [Full-text]
60. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.
    Br J Cancer, 102(6): 981-6. [Abstract] [Full-text]
61. Indications for catheter-directed thrombolysis in the management of acute proximal deep venous thrombosis.
    Arterioscler Thromb Vasc Biol, 30(4): 669-74. [Abstract] [Full-text]
62. Chemotherapy for advanced gastric cancer.
    Cochrane Database Syst Rev, 3: CD004064. [Abstract] [Full-text]
63. Emergency sclerotherapy versus vasoactive drugs for bleeding oesophageal varices in cirrhotic patients.
    Cochrane Database Syst Rev, 3: CD002233. [Abstract] [Full-text]
64. Fibrinolytic agents for peripheral arterial occlusion.
    Cochrane Database Syst Rev, 3: CD001099. [Abstract] [Full-text]
65. Antibiotic prophylaxis for surgery for proximal femoral and other closed long bone fractures.
    Cochrane Database Syst Rev, 3: CD000244. [Abstract] [Full-text]
66. Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP).
    Ann Hematol, 89(5): 489-97. [Abstract] [Full-text]
67. Salvage treatment with upfront melphalan 100 mg/m(2) and consolidation with novel drugs for fulminant progression of multiple myeloma.
    Ann Hematol, 89(5): 483-7. [Abstract] [Full-text]
68. Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study.
    Ann Hematol, 89(5): 475-82. [Abstract] [Full-text]
69. Ultrasound as a screening tool for proceeding with caudal epidural injections.
    Arch Phys Med Rehabil, 91(3): 358-63. [Abstract] [Full-text]
70. Docetaxel, carboplatin and 5-fluorouracil (TCF) chemotherapy in patients with unresectable metastatic carcinoma of cervix.
    Gynecol Oncol, 117(1): 65-9. [Abstract] [Full-text]
71. Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved.
    J Cancer Res Clin Oncol, 136(5): 639-50. [Abstract] [Full-text]
72. Controlled reagent transport in disposable 2D paper networks.
    Lab Chip, 10(7): 918-20. [Abstract] [Full-text]
73. Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma.
    Cancer Genet Cytogenet, 198(1): 40-6. [Abstract] [Full-text]
74. Cancer and inflammation: implications for pharmacology and therapeutics.
    Clin Pharmacol Ther, 87(4): 401-6. [Abstract] [Full-text]
75. Interleukin-6 as a therapeutic target in candidate inflammatory diseases.
    Clin Pharmacol Ther, 87(4): 483-7. [Abstract] [Full-text]
76. Effects of high-dose chemotherapy on bone marrow multipotent mesenchymal stromal cells isolated from lymphoma patients.
    Exp Hematol, 38(4): 292-300.e4. [Abstract] [Full-text]
77. Restricted peri-operative fluid administration adjusted by serum lactate level improved outcome after major elective surgery for gastrointestinal malignancy.
    Surgery, 147(4): 542-52. [Abstract] [Full-text]
78. Targeting of drugs and nanoparticles to tumors.
    J Cell Biol, 188(6): 759-68. [Abstract] [Full-text]
79. Effects of growth hormone and thyroxine replacement therapy on insulin signaling in Ames dwarf mice.
    J Gerontol A Biol Sci Med Sci, 65(4): 344-52. [Abstract] [Full-text]
80. Xylan-regulated delivery of human keratinocyte growth factor-2 to the inflamed colon by the human anaerobic commensal bacterium Bacteroides ovatus.
    Gut, 59(4): 461-9. [Abstract] [Full-text]
81. Augmentation of therapeutic efficacy in drug-resistant tumor models using ceramide coadministration in temporal-controlled polymer-blend nanoparticle delivery systems.
    AAPS J, 12(2): 171-80. [Abstract] [Full-text]
82. The rise and fall of gabapentin for bipolar disorder: a case study on off-label pharmaceutical diffusion.
    Med Care, 48(4): 372-9. [Abstract] [Full-text]
83. Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer.
    BMC Cancer, 10: 85. [Abstract] [Full-text]
84. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.
    Blood, 115(12): 2372-9. [Abstract] [Full-text]
85. Neoadjuvant chemoradiation with paclitaxel/carboplatin for selected Stage III non-small-cell lung cancer: long-term results of a trimodality Phase II protocol.
    Int J Radiat Oncol Biol Phys, 76(5): 1376-81. [Abstract] [Full-text]
86. Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082.
    Int J Radiat Oncol Biol Phys, 76(5): 1305-13. [Abstract] [Full-text]
87. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for invasive anal carcinoma in human immunodeficiency virus-positive patients receiving highly active antiretroviral therapy.
    Int J Radiat Oncol Biol Phys, 76(5): 1425-32. [Abstract] [Full-text]
88. Inverse association of female hormone replacement therapy with age-related macular degeneration and interactions with ARMS2 polymorphisms.
    Invest Ophthalmol Vis Sci, 51(4): 1873-9. [Abstract] [Full-text]
89. Episcleral implants for topotecan delivery to the posterior segment of the eye.
    Invest Ophthalmol Vis Sci, 51(4): 2126-34. [Abstract] [Full-text]
90. Surgical procedures and morbidities of diaphragmatic surgery in patients undergoing initial or interval debulking surgery for advanced-stage ovarian cancer.
    J Am Coll Surg, 210(4): 509-14. [Abstract] [Full-text]
91. Treatment of a pelvic arteriovenous malformation by stent graft placement combined with sclerotherapy.
    J Vasc Surg, 51(4): 1006-9. [Abstract] [Full-text]
92. Changes in health-related quality of life after ultrasound-guided foam sclerotherapy for great and small saphenous varicose veins.
    J Vasc Surg, 51(4): 913-20. [Abstract] [Full-text]
93. Prospective determination of candidates for thrombolysis in patients with acute proximal deep vein thrombosis.
    J Vasc Surg, 51(4): 908-12. [Abstract] [Full-text]
94. Racial disparities in prescriptions for cardioprotective drugs and cardiac outcomes in Veterans Affairs Hospitals.
    Am J Cardiol, 105(7): 1019-23. [Abstract] [Full-text]
95. Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR.
    Ophthalmology, 117(4): 747-56.e4. [Abstract] [Full-text]
96. The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity.
    Toxicol Appl Pharmacol, 244(2): 190-5. [Abstract] [Full-text]
97. The effect of oral rehydration solution and recommended home fluids on diarrhoea mortality.
    Int J Epidemiol, 39: i75-87. [Abstract] [Full-text]
98. Long-term results of riboflavin ultraviolet a corneal collagen cross-linking for keratoconus in Italy: the Siena eye cross study.
    Am J Ophthalmol, 149(4): 585-93. [Abstract] [Full-text]
99. Confusion about epinephrine dosing leading to iatrogenic overdose: a life-threatening problem with a potential solution.
    Ann Emerg Med, 55(4): 341-4. [Abstract] [Full-text]
100. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor for elderly patients with previously untreated acute myeloid leukemia.
     Leuk Res, 34(5): 610-4. [Abstract] [Full-text]
101. mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein.
     Leuk Res, 34(5): 641-8. [Abstract] [Full-text]
102. Chemical induction of misfolded prion protein conformers in cell culture.
     J Biol Chem, 285(14): 10415-23. [Abstract] [Full-text]
103. A simple yeast-based system for analyzing inhibitor resistance in the human cancer drug targets Hsp90alpha/beta.
     Biochem Pharmacol, 79(11): 1581-8. [Abstract] [Full-text]
104. Thymoquinone poly (lactide-co-glycolide) nanoparticles exhibit enhanced anti-proliferative, anti-inflammatory, and chemosensitization potential.
     Biochem Pharmacol, 79(11): 1640-7. [Abstract] [Full-text]
105. Ryanodine receptor calcium channels and their partners as drug targets.
     Biochem Pharmacol, 79(11): 1535-43. [Abstract] [Full-text]
106. Stroke after prolonged air travel associated with a pulmonary arteriovenous malformation.
     J Neurol Sci, 292(1): 99-100. [Abstract] [Full-text]
107. The effect of strain rate on the precision of penetration of short densely-packed microprojection array patches coated with vaccine.
     Biomaterials, 31(16): 4562-72. [Abstract] [Full-text]
108. Controlling silk fibroin particle features for drug delivery.
     Biomaterials, 31(16): 4583-91. [Abstract] [Full-text]
109. The effects of controlled HGF delivery from an affinity-binding alginate biomaterial on angiogenesis and blood perfusion in a hindlimb ischemia model.
     Biomaterials, 31(16): 4573-82. [Abstract] [Full-text]
110. Estrogen therapy and bone mineral density in African-American and Caucasian women.
     Am J Epidemiol, 171(7): 808-16. [Abstract] [Full-text]
111. Short-term hormone treatment modulates emotion response circuitry in postmenopausal women.
     Fertil Steril, 93(6): 1929-37. [Abstract] [Full-text]
112. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I).
     Br J Cancer, 102(7): 1123-8. [Abstract] [Full-text]
113. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia.
     Br J Cancer, 102(7): 1129-36. [Abstract] [Full-text]
114. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer.
     Br J Cancer, 102(7): 1099-105. [Abstract] [Full-text]
115. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.
     Br J Cancer, 102(7): 1106-12. [Abstract] [Full-text]
116. Impact of tumor response on survival after radiochemotherapy in locally advanced rectal carcinoma.
     Am J Surg Pathol, 34(4): 562-8. [Abstract] [Full-text]
117. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis.
     J Clin Oncol, 28(10): 1706-13. [Abstract] [Full-text]
118. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.
     J Clin Oncol, 28(10): 1645-51. [Abstract] [Full-text]
119. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma.
     J Clin Oncol, 28(10): 1780-7. [Abstract] [Full-text]
120. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.
     J Clin Oncol, 28(10): 1638-44. [Abstract] [Full-text]
121. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
     J Clin Oncol, 28(10): 1756-65. [Abstract] [Full-text]
122. Dose-intensified treatment of Burkitt lymphoma and B-cell lymphoma unclassifiable, (with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma) in young adults (<50 years): a comparison of two adapted BFM protocols.
     Am J Hematol, 85(4): 261-3. [Abstract] [Full-text]
123. Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysis.
     Am J Hematol, 85(4): 255-60. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.